

30th October 2017

AirSonea Generation 2 Breath Sensor Update

The final step to commercialisation is replacing the 2013 AirSonea breath sensor with a 2018 next generation device. This ensures the compatibility between the breath sensor and Respi's recently launched software platform housing Respi's wheezeRATE algorithm.

Better ergonomics deliver a more user-friendly device by making it easier to grip and place in the optimum position on the neck for recording breath sounds. Updated components and skilled engineering will improve the quality of the sound files being transmitted to the AirSonea App for accurate analysis.

As the primary market is children and young people, an important consideration in the design of the breath sensor is its internal and external robustness.

Chairman Leon L'Huillier states "Approaching the 2018 launch, the company is in the strongest position since I commenced with Respi in 2014. Respi is delighted with the appointment of Mario Gattino, a former Senior Global Pfizer Executive, as Chief Executive Officer. He is ideally suited to lead the company through its commercialisation phase.

Recent developments in the UK's National Health Service, a key target market, identify the need for greater asthma symptom monitoring capabilities, particularly wheeze and the use of technology."

AirSonea is a digital self-management tool that enables users to seamlessly track and share their wheeze and triggers and medication use for better control of their asthma and improved quality of life.

As previously announced, Respi's breath sensor development will take a minimum of six months.



AirSonea 2013 | AirSonea 2018 concept render only

Leon L'Huillier
Chairman

Ph: 1800 476 632

About Respi

Respi Limited (ASX:RSH) is a health technology company leading the way in the development of innovative devices and mobile health apps to improve the management of chronic and costly respiratory disorders such as asthma and COPD. Building on decades of experience in the research and development of cutting-edge clinical products for hospitals, the company has first-mover advantage in providing broad access to its proprietary acoustic based clinical solutions for remote monitoring with the development of a suite of over-the-counter connected devices.

Health authorities universally agree that mHealth solutions can transform asthma care and health conscious consumers are rapidly embracing patient self-management with the aid of smartphones, the growth engine for Respi's flagship product, AirSonea®. With the addition of new products, including a connected device for nocturnal monitoring in development, Respi has a captive market, globally, of parents and carers of young children who cannot perform lung function tests. Respi products have been cleared for use by the US Food and Drug Administration, the European Union CE, the Australian TGA and the commencement of an approval process for Asian markets has begun.

Respi is especially proud of its recent de-risking of milestones. The substantial achievements over the past 18 months place Respi in a lower risk position and on the cusp of commercialisation compared to the vast majority of medical device and biotech companies.

For personal use only